<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389450</url>
  </required_header>
  <id_info>
    <org_study_id>PLX-COV-01</org_study_id>
    <nct_id>NCT04389450</nct_id>
  </id_info>
  <brief_title>Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pluristem Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pluristem Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will examine if a new treatment of Mesenchymal Stems Cells (called
      PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover
      more quickly with less complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ventilator free days</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>COVID</condition>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>PLX-PAD interval high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLX-PAD will be administered via 15 IM injections (1 mL each). Each subject will be treated twice, with an interval of 1 week between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLX-PAD low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLX-PAD 300, single administration, second administration of placebo after 1 week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, two administrations, 1 week apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLX-PAD high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLX-PAD, single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PLX-PAD</intervention_name>
    <description>PLX-PAD, allogeneic ex vivo expanded placental mesenchymal-like adherent stromal cells</description>
    <arm_group_label>PLX-PAD high dose</arm_group_label>
    <arm_group_label>PLX-PAD interval high dose</arm_group_label>
    <arm_group_label>PLX-PAD low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution for injection</description>
    <arm_group_label>Control Group A</arm_group_label>
    <arm_group_label>Control Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent, or with a legal representative
             who can provide informed consent.

          -  Male or non-pregnant female adult 40-80 years of age at time of enrollment.

          -  Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, in any specimen up to
             21 days prior to randomization.

          -  Meets definition of ARDS according to Berlin criteria.

        Key Exclusion Criteria:

          -  Body weight under 55 kg (121 lbs)

          -  Serum creatinine level of over 1.5 mg/dL at time of randomization.

          -  Total Bilirubin â‰¥2 mg/dL at time of randomization.

          -  Known allergy to any of the following: dimethyl sulfoxide (DMSO), human serum albumin,
             bovine serum albumin.

          -  Stroke or acute myocardial infarction/unstable angina within 3 months prior to
             randomization.

          -  Chronic Obstructive Pulmonary disease GOLD stage above II.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Holy Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suraj Saggar, Dr.</last_name>
      <phone>201-503-0660</phone>
      <email>surajsaggar@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Sanders, MD</last_name>
      <phone>718-283-7686</phone>
      <email>PaSaunders@maimonidesmed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Gautam, Dr.</last_name>
      <phone>215-955-5161</phone>
      <email>Gautam.George@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <link>
    <url>http://www.pluristem.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

